|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
26.05.26 - 22:06
|
ICON Schedules Fourth Quarter and Full Year 2025 Earnings Conference Call and Acknowledges Receipt of Deficiency Notice from Nasdaq (Business Wire)
|
|
|
DUBLIN--(BUSINESS WIRE)--ICON plc (NASDAQ: ICLR), a world-leading clinical research organization, today announced that it will release financial results for the fourth quarter and full year 2025 results after the market closes on Wednesday, May 27, 2026. The Company will hold a conference call and webcast to discuss its financial results and performance on Thursday, May 28, 2026 at 8:00am ET.
The Company also announced that, as expected, as a consequence of not yet having filed its Annual Report on Form 20-F for the year ended December 31, 2025 (the “Form 20-F”), the Company has received a written notice from Nasdaq indicating that it is not in compliance with Nasdaq Listing Rule 5250(c)(1) (the “Listing Rule”), which requires timely filing of all required periodic financial reports with the U.S. Securities and Exchange Commission.
The notice has no immediate impact on the listing or trading of the Company's securities. Nasdaq has provided the Company with 60 calendar days from the date of the no...
|
|
|
|
|
|
|
26.05.26 - 13:03
|
Alkermes to Showcase Leadership in Psychiatry and Orexin Biology With New Data at the American Society of Clinical Psychopharmacology Annual Meeting (Business Wire)
|
|
|
— Company to Present 11 Posters Demonstrating Commitment to Advancing Innovative Research for People Living With Chronic Psychiatric and Neurological Disorders —DUBLIN--(BUSINESS WIRE)--Alkermes plc (Nasdaq: ALKS) today announced plans to present clinical and real-world data related to the company's psychiatry and orexin portfolios at the American Society of Clinical Psychopharmacology Annual Meeting, taking place May 26-29, 2026 in Miami. The poster presentations include data related to Alkermes' proprietary commercial medicines, LYBALVI® (olanzapine and samidorphan) and ARISTADA® (aripiprazole lauroxil), and its pipeline of investigational orexin 2 receptor agonists, including alixorexton, ALKS 4510 and ALKS 7290.
“Alkermes brings decades of experience advancing innovative medicines in neuroscience and psychiatry, underpinned by deep scientific expertise. Our poster presentations at ASCP reflect our continued commitment to advancing both the understanding of, and treatment options for, complex...
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
20.05.26 - 15:48
|
Medtronic To Acquire SPR Therapeutics (AFX)
|
|
|
WASHINGTON (dpa-AFX) - Medtronic plc (MDT) announced intent to acquire SPR Therapeutics, Inc. (SPR), a privately held medical technology company. The transaction consists of an upfront cash paymen......
|
|
|
|
|
19.05.26 - 18:30
|
UBS Just Upgraded Jazz Pharma to Buy. New $307 Price Target Could Signal a Turning Point (24/7 Wall St.)
|
|
|
One of Wall Street's major firms just put its stamp of approval on a specialty pharma name that has been quietly rallying. UBS upgraded Jazz Pharmaceuticals (NASDAQ:JAZZ) to Buy with a $307 price target, signaling the firm sees a constructive setup the market hasn't yet priced. For long-term investors, the call lands at a moment ... UBS Just Upgraded Jazz Pharma to Buy. New $307 Price Target Could Signal a Turning Point...
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
